FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Chang David D 2. Date of Event Requiring Statement (Month/Day/Year) 10/10/2018				ment	3. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO]							
(Last) (First) (Middle) 210 EAST GRAND AVENUE					4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) SOUTH SAN FRANCISCO	CA	94080			X	Officer (give title below) President and C	Other (sp below) CEO	ecify	Appli	cable Line) Form filed by	/Group Filing (Check y One Reporting Person y More than One erson	
(City) ((State)	(Zip)										
		7	Γable I - Nor	n-Derivati	ive Se	ecurities Beneficiall	y Owned	l				
1. Title of Security (Instr. 4)						nt of Securities ally Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock						1,955,625	D					
Common Stock						1,071,892	I		See footnote ⁽¹⁾			
Common Stock						848,022	I		See footnote ⁽²⁾			
Common Stock						848,022	I		See footnote ⁽³⁾			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
Expiration			Expiration D	2. Date Exercisable and Expiration Date (Month/Day/Year)		d 3. Title and Amount of Securi Underlying Derivative Securi		or Exe	nversion Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Price of Derivation	tive	Direct (D) or Indirect (I) (Instr. 5)		
Series A Convertible Preferred Stock			(4)	(4)		Common Stock	29,946	0.0	00	I	See footnote ⁽¹⁾	

Explanation of Responses:

- 1. Securities held in the name of the Chang 2006 Family Trust.
- 2. Securities held in the name of the Julia Chang 2018 Irrevocable Trust, of which the reporting person is Trustee and his daughter is the beneficiary.
- 3. Securities held in the name of the Robert Chang 2018 Irrevocable Trust, of which the reporting person is Trustee and his son is the beneficiary.
- 4. Each share of Series A Convertible Preferred Stock is convertible into 5.25 shares of Common Stock. The Series A Convertible Preferred Stock has no expiration date.

Remarks:

/s/ Veer Bhavnagri, Attorneyin-Fact

10/10/2018

** Signature of Reporting Person

Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Eric Schmidt, Jack Chen, David Tanen and Veer Bhavnagri of Allogene Therapeutics, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in fact and agent to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of September, 2018.

/s/ David D. Chang